Cinda Biotech (01801)'s product revenue in the first half of the year exceeded 8.2 billion yuan, up more than 55% year-on-year

Zhitong Finance App News, Cinda Biotech (01801) announced that in the first half of 2026, the company's product revenue exceeded RMB 8.2 billion, an increase of more than 55% over the previous year. Among them, the company achieved product revenue of more than RMB 4.3 billion in the second quarter, an increase of about 60% over the previous year. This strong performance fully reflects the continued effectiveness of the company's “two-wheel drive” strategy. The comprehensive product line has maintained strong growth, and core products such as Xinermei® (Maxidopeptide Injection), Cinpirac® (Tolexizumab Injection), and Cinbimin® (Tetuumab N01 Injection) have performed well and have become an important driving force for revenue growth. At the same time, the company's leading edge in the field of oncology continues to stabilize. The market penetration rate of the five new tyrosine kinase inhibitors (TKIs) included in the National Health Insurance Catalogue (NRDL) continues to increase, and revenue volume accelerates. Furthermore, the company successfully expanded its strategy into the commercialization field of treatment of breast cancer, and reached a commercial cooperation with Eli Lilly® (abecilil tablets) in mainland China, laying a solid foundation for the company's subsequent breast cancer pipeline development and market expansion.

In the first half of 2026, thanks to strong growth in leading revenue scale and diversified product portfolio, the company continued to consolidate its position as a leading biopharmaceutical company in China. In terms of global innovation, the company is promoting three core innovation assets into global phase III clinical research and continuing to expand next-generation innovation pipelines in the fields of oncology, cardiovascular and metabolic (CVM), autoimmunity, and ophthalmology. At the same time, the company has collaborated on more than 20 projects with multinational pharmaceutical companies such as Pfizer, Eli Lilly, Takeda and Roche, including five co-development and co-commercialization (Co-Co) pipelines, and its global innovation capabilities continue to be recognized. Looking forward to the future, the company will rely on the continuous expansion of domestic business and the continuous advancement of the global innovation pipeline to accelerate its international layout and steadily move towards the long-term vision of “becoming a world-class biopharmaceutical company”.